Clinical Trial

A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the efficacy and safety of sintilimab combined with ramucirumab and paclitaxel in the treatment of advanced gastric cancer patients with short-term recurrence after postoperative adjuvant therapy, and to identify efficacy-related biomarkers to guide subsequent individualized treatment.
Trial Details
NCT Number NCT07669740
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Gastric Cancer (Diagnosis)
Enrollment 30 participants
Start Date 2026-07-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-25